Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy
Malignant tumors are diseases that seriously threaten human health and social development. Traditional tumor therapies such as surgery, radiotherapy, chemotherapy and targeted therapy cannot fully meet the needs of clinical treatment, and emerging immunotherapy has become a research hotspot in the field of tumor treatment. Immune checkpoint inhibitors (ICIs) have been approved as a tumor immunotherapy method for the treatment of various tumors, such as lung cancer, liver cancer, stomach cancer and colorectal cancer, etc. However, during the clinical use of ICIs, only a small number of patients experienced durable responses, which also led to drug resistance and adverse reactions. Therefore, the identification and development of predictive biomarkers is crucial to improve the therapeutic efficacy of ICIs. The predictive biomarkers of tumor ICIs mainly include tumor biomarkers, tumor microenvironment biomarkers, circulation-related biomarkers, host environmental biomarkers and combinatorial biomarkers. They are of great significance for screening, individualized treatment and prognosis evaluation of tumor patients. This article reviews the advances of predictive markers for tumor ICIs therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Sheng wu gong cheng xue bao = Chinese journal of biotechnology - 39(2023), 4 vom: 25. Apr., Seite 1403-1424 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Guo, Rui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 10.05.2023 Date Revised 10.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.13345/j.cjb.220650 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356574520 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356574520 | ||
| 003 | DE-627 | ||
| 005 | 20231226070743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.13345/j.cjb.220650 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356574520 | ||
| 035 | |a (NLM)37154314 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Guo, Rui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2023 | ||
| 500 | |a Date Revised 10.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Malignant tumors are diseases that seriously threaten human health and social development. Traditional tumor therapies such as surgery, radiotherapy, chemotherapy and targeted therapy cannot fully meet the needs of clinical treatment, and emerging immunotherapy has become a research hotspot in the field of tumor treatment. Immune checkpoint inhibitors (ICIs) have been approved as a tumor immunotherapy method for the treatment of various tumors, such as lung cancer, liver cancer, stomach cancer and colorectal cancer, etc. However, during the clinical use of ICIs, only a small number of patients experienced durable responses, which also led to drug resistance and adverse reactions. Therefore, the identification and development of predictive biomarkers is crucial to improve the therapeutic efficacy of ICIs. The predictive biomarkers of tumor ICIs mainly include tumor biomarkers, tumor microenvironment biomarkers, circulation-related biomarkers, host environmental biomarkers and combinatorial biomarkers. They are of great significance for screening, individualized treatment and prognosis evaluation of tumor patients. This article reviews the advances of predictive markers for tumor ICIs therapy | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a predictive biomarkers | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a tumor | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Li, Xiaoning |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Mingxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Youfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zhao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Sheng wu gong cheng xue bao = Chinese journal of biotechnology |d 1997 |g 39(2023), 4 vom: 25. Apr., Seite 1403-1424 |w (DE-627)NLM093700067 |x 1872-2075 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:4 |g day:25 |g month:04 |g pages:1403-1424 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.13345/j.cjb.220650 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 4 |b 25 |c 04 |h 1403-1424 | ||